Eligibility, any sex, with Clostridium Difficile Infection. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The Number of Cases of CDIPrimary· Samples were received between July and December 2018 (at time of diarrheal episode) and test performed during that timeframe to identify the number of CDI cases (positive test result) and the number of CDI negative controls (negative test result).
This outcome measure is to indicate the number of participants with a sample that returned a positive test result (=CDI cases) at the coordinating laboratory from the overall total number of participants. The number of CDI cases and negative controls are the number of participants with a sample that returned a positive or negative test result, respectively. Therefore the "CDI negative controls" arm did not return a positive test result. The proportion of participants that returned a positive test result compared to the total of participants (=number of participants in the "CDI cases" arm divid
Group
Value
95% CI
CDI Cases
103
CDI Negative Controls
0
Sponsor's own description
Clostridium difficile infection (CDI) is the most common cause of antibiotic associated diarrhoea in the western world. The infection causes significant diarrhoea, which in some cases can be serious and lead to secondary complications and even death. The infection is particularly an issue in elderly, frail patient, who are often already burdened with several other medical issues. Recent work has demonstrated that numerous cases are missed, either due to inadequate diagnostic tests or lack of clinical suspicion.
The public-private partnership in COMBACTE-CDI will quantify the burden of CDI via a large, complex, multi-centre, multi-country study, and describe current management practices. An increased understanding of the CDI burden across Europe and better understanding of transmission of the organism will provide a basis for the further development of public health interventions and practices.
Based on a previous successful study model (EUCLID), hospitals/laboratories of interest which carry out diagnostic testing of samples from both in-patients and community patients (including Long-Term Care Facilities patients) will be approached for inclusion in the study. Samples sent to the sites on the selected study date (regardless of test requested) will be tested at a central laboratory for CDI to look for missed cases of CDI. A follow up case/control study will collect data on outcomes and risk factors. Data will be used to construct transmission models and cost effective-ness models. Ultimately, a best practice model for CDI management will be developed.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator
· not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive
· NA
· not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness
· NA
· not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt
· not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms
· not yet recruiting
Other recruiting trials for Clostridium Difficile Infection
Currently open trials in the same condition.
NCT07221370 — Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
· Phase 2, PHASE3
· recruiting
NCT06703918 — Study on Clostridium Difficile Infection in Infants
· recruiting
NCT04305769 — Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
· Phase 2
· recruiting
NCT04014413 — Safety and Efficacy of Fecal Microbiota Transplantation
· NA
· recruiting
NCT03562741 — Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
· NA
· recruiting
Other University of Leeds trials
Trials by the same sponsor.
NCT07488143 — AI-assisted Continuous Stratification in Neurorehabilitation of Stroke Using Personalized Digital Twins
· NA
· not yet recruiting
NCT07409363 — Non-invasive Vagus Nerve Stimulation for Chronic Musculoskeletal Pain
· NA
· not yet recruiting
NCT07247812 — tSCS in Children and Young People With HCP
· NA
· not yet recruiting
NCT07181915 — Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits
· NA
· active not recruiting
NCT06240403 — Digoxin and Senolysis in Heart Failure and Diabetes Mellitus
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Leeds
Last refreshed: 9 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03503474.